Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19
Clinical Trial
[키워드] 95% CI
ARDS
BALF
Bronchoalveolar lavage fluid
cleaving
clinical
clinical trial
complexes
COVID - 19
COVID-19
Degradation
develop
DNA
Dornase alfa
Effect
Effects
evaluate the effect
Extracellular
extracellular DNA
fraction
Genentech
improvement
Inhaled
inhibited
Lung compliance
MPO
NET
NETs
Neutrophil extracellular trap
non-randomized
oxygen
oxygen saturation
Oxygenation
P-value
PaO
Patient
patients with ARDS
performed
pilot study
Pneumonia
positive
reduction in
Registration
respiratory
Respiratory failure
Result
secondary to
Severe case
Structure
sustained
therapy
treatment group
Viral
[DOI] 10.3389/fimmu.2021.714833 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.3389/fimmu.2021.714833 PMC 바로가기 [Article Type] Clinical Trial